Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

Randomized prospective comparative study of platelet-rich plasma versus conventional compression in treatment of post-phlebitic venous ulcer.

Authors:
Abdelrahman W Shehab Ahmed Eleshra Elyamani Fouda Hossam Elwakeel Mohamed Farag

Vascular 2022 May 22:17085381221104629. Epub 2022 May 22.

Department of Vascular Surgery, Faculty of Medicine, 68780Mansoura University, Mansoura, Egypt.

Objectives: to assess the safety and efficacy of platelet-rich plasma (PRP) as adjunctive to compression therapy for post-phlebitic venous ulcers.

Methods: This is a single-center randomized controlled trial on patients with persistent chronic post-phlebitic lower limb venous ulcers from March 2019 to March 2020. Patients were randomly allocated to one of two equal cohort groups. Patients group in which patients underwent combined PRP with compression therapy versus control group in which patients underwent placebo+ compression therapy alone. The primary endpoint of the study was the improvement in ulcer topographic measurement. Secondary endpoints included ulcer healing parameters, possible healing factors, reduction in pain score (VAS), and the achievement of complete healing.

Results: Forty patients were available equally for randomization and analysis in both groups. The median number of PRP applications for every patient in the patient group was 6 (ranging from 3 to 6). There was a significant decline in the median length, width, and depth of ulcers in the patients group versus control group. Consequently, there was a significant decline of the median ulcer area, in the patient group versus control group (4 (3-9) cm vs. 10 (6-14) cm, = .036). Also, the median volume of the ulcers showed a significant decline in the patient group versus control group (1 (.7-3) cm vs 3 (2-6) cm, = .008). Complete healing was achieved in 45% of patient group. There was a significant decline in pain scores at 3- and 6 months from the therapy starting point in both groups (patient group: pre-VAS = 6.5 vs. post(3 months)-VAS = 1 vs. post(6 months)-VAS = 0.5) and (control group: pre-VAS = 6.4 vs. post(3 months)-VAS = 4.5 vs. post(6 months)-VAS = 2.2), ( < .0001 for each). On the other hand, the decline in pain scores between both groups was statistically significant in favor of the patient group, (post (3 months); PRP-VAS = 1 vs. control-VAS = 4.5, and post(6 months); PRP-VAS = 0.5 vs. control-VAS = 2.2), ( < .0001).

Conclusion: Platelet-rich plasma as an adjunct to compression therapy for chronic post-phlebitic venous ulcers is safe and effective as regards the ulcer healing and improvement of pain score. PRP may be useful adjunct in treatment of post-phlebitic venous ulcer. However, larger trials are warranted.

Download full-text PDF

 Source
http://dx.doi.org/10.1177/17085381221104629DOI Listing
May 2022

Publication Analysis

Top Keywords

patient group
24
control group
20
post-phlebitic venous
16
compression therapy
16
versus control
16
group
13
group versus
12
platelet-rich plasma
12
group patients
8
treatment post-phlebitic
8
patients underwent
8
group pre-vas
8
patients group
8
chronic post-phlebitic
8
pain scores
8
decline pain
8
venous ulcer
8
venous ulcers
8
decline median
8
pain score
8

Keyword Occurance

Similar Publications

Everyone's a winner if we test less: the CODA action plan.

Authors:
Oliver Walsh Roger Harris Oliver Flower Matthew Anstey Forbes McGain

Aust Health Rev 2022 Jul 1. Epub 2022 Jul 1.

In this era of 'Choosing Wisely,' we present a four-step action plan to reduce unnecessary pathology testing and the associated patient harm (blood loss through repeated phlebotomy), economic cost and environmental impact. The authors are experts from the CODA group; a medical education and health-promotion charity that aims to build on the Choosing Wisely initiative to provide meaningful and sustainable actions to reduce the carbon footprint of healthcare, globally. Pathology testing is expensive and carbon-intensive, with as many as half of all tests being not clinically indicated. Read More

View Article and Full-Text PDF
July 2022
Similar Publications

Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure.

Authors:
J David Smeijer Jeroen Koomen Donald E Kohan John J V McMurray George L Bakris Ricardo Correa-Rotter Fan-Fan Hou James L Januzzi Dalane W Kitzman Daniel M Kolansky Hirofumi Makino Vlado Perkovic Sheldon Tobe Hans-Henrik Parving Dick de Zeeuw Hiddo J L Heerspink

JACC Heart Fail 2022 Jul 4;10(7):498-507. Epub 2022 May 4.

Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, the Netherlands; George Institute for Global Health, Newtown, Australia. Electronic address:

Background: The endothelin receptor antagonist atrasentan reduced the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease (CKD) in the SONAR (Study of Diabetic Nephropathy with Atrasentan) trial, although with a numerically higher incidence of heart failure (HF) hospitalization.

Objectives: The purpose of this study was to assess if early changes in B-type natriuretic peptide (BNP) and body weight during atrasentan treatment predict HF risk.

Methods: Participants with type 2 diabetes and CKD entered an open-label enrichment phase to assess response to atrasentan 0. Read More

View Article and Full-Text PDF
July 2022
Similar Publications

Hospitalization Patterns and Impact of a Magnetically-Levitated Left Ventricular Assist Device in the MOMENTUM 3 Trial.

Authors:
Himabindu Vidula Koji Takeda Jerry D Estep Scott C Silvestry Carmelo Milano Joseph C Cleveland Daniel J Goldstein Nir Uriel Robert L Kormos Nicholas Dirckx Mandeep R Mehra

JACC Heart Fail 2022 Jul 8;10(7):470-481. Epub 2022 Jun 8.

Center for Advanced Heart Disease, Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, Massachusetts, USA. Electronic address:

Background: In the MOMENTUM 3 (Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3) pivotal trial, the HeartMate 3 (HM3) fully magnetically levitated left ventricular assist device (LVAD) demonstrated superiority over the axial-flow HeartMate II (HMII) LVAD. The patterns and predictors of hospitalizations with the HM3 LVAD have not been characterized.

Objectives: This study sought to determine causes, predictors, and impact of hospitalizations during LVAD support. Read More

View Article and Full-Text PDF
July 2022
Similar Publications

Multimodal imaging analysis for the impact of retinal peripheral lesions on central neurovascular structure and retinal function in type 2 diabetes with diabetic retinopathy.

Authors:
Xuenan Zhuang Ruoyu Chen Anyi Liang Jie Yao Zicheng Wang Yesheng Chen Kangyan Zheng Peiyao Lu Liang Zhang Dan Cao

Br J Ophthalmol 2022 Jun 30. Epub 2022 Jun 30.

Department of Ophthalmology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China

Objectives: To explore the possible role of peripheral lesions (PLs) detected by ultrawide field (UWF) imaging system on central neurovascular structure and retinal function.

Methods: Ninety-seven diabetic patients were included in this cross-sectional study using UWF pseudocolour colour imaging with Optos Daytona (Optos, PLC). UWF images were graded as with predominantly peripheral lesions (PPLs) and without PPL. Read More

View Article and Full-Text PDF
June 2022
Similar Publications

Consent for orthopaedic trauma surgery during the COVID-19 pandemic.

Authors:
Hussain Selmi Andrew Davies Joseph Walker Toby Heaton Sanjeeve Sabharwal Melanie Dani Michael Fertleman Peter Reilly

BMJ Open Qual 2022 Jun;11(2)

Department of Trauma and Orthopaedics, Imperial College Healthcare NHS Trust, London, UK.

Introduction: The COVID-19 pandemic has brought a series of new challenges to the management of surgical patients. The consent process relies on a foundation of open and non-coerced discussion between clinician and patient, which includes all the potential risks of surgery. This must be updated to incorporate the additional risks of surgery during the pandemic including infection with the SARS-CoV-2 and increased risks of complications with the potential requirement for intensive care support. Read More

View Article and Full-Text PDF
June 2022
Similar Publications
}